Closing the Digital Gap: FDA’s Oversight of Social Media
January 11th 2023The parameters governing pharma promotional speech in digital and social media have struggled to keep pace with the rapidly evolving healthcare communications landscape. How can FDA play catch-up in advancing an agenda more reflective of industry and patient needs?
Stars Aligned for Pricing Model? Value-Based Contracts May be Poised for Takeoff
January 11th 2023As new forms of cell and gene therapies continue to be developed, life sciences companies and payers need to find alternative ways to pay for these expensive treatments. Value-based contracts, though slow to gain traction so far, may provide the solution these groups are looking for.
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
January 11th 2023Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.